Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the effect of i.v. Bondronat [ibandronic acid] followed by maintenance treatment with oral Bondronat on pain response in patients with bone metastases from breast cancer or multiple myeloma experiencing moderate to severe pain

Trial Profile

Evaluation of the effect of i.v. Bondronat [ibandronic acid] followed by maintenance treatment with oral Bondronat on pain response in patients with bone metastases from breast cancer or multiple myeloma experiencing moderate to severe pain

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibandronic acid (Primary)
  • Indications Advanced breast cancer; Cancer metastases; Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Roche

Most Recent Events

  • 23 Feb 2010 Planned number of patients changed from 60 to 53 as reported by ROche record.
  • 16 Apr 2008 Status changed from in progress to completed.
  • 09 Jan 2008 Status changed from recruiting to in progress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top